# Lihe Chemistry

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lihe-chemistry

- Industry: Pharmaceuticals
- Headquarters: Wuhan, China
- Total disclosed funding: $13M
- Latest round: Series A (Mar 13, 2018)
- Investors on record: 3

## About

Established in 2013 and based in Wuhan, China, Lihe Chemistry operates as a healthcare company that specializes in the production and sales of chemically synthesized active ingredients for pharmaceuticals. In March 2018, the company raised CNY 50 million in series A+ funding led by new investor China Merchants Bank,returning investor Wuhan East-Lake Venture also participated in this funding.

The company focuses on the production and sale of chemically synthesized active ingredients for pharmaceuticals. Products include pharmaceutical intermediates and APIs. Pharmaceutical intermediates include esomeprazole sodium and esomeprazole magnesium and their intermediates and major impurities, and aprepitant intermediates.

The company generates revenue by providing chemically synthesized active ingredients for pharmaceuticals.

## Funding rounds

- Series A, Mar 13, 2018, $7.9M — East Lake Ventures, China Merchants Bank
- Series A, Mar 30, 2017, $5.1M — East Lake Ventures, Ch-Gemstone Capital

## Investors

- East Lake Ventures (https://capitalatlas.ai/funds/east-lake-ventures) — Series A
- Ch-Gemstone Capital — Series A
- China Merchants Bank — Series A